Cargando…

Immunologic treatments for precancerous lesions and uterine cervical cancer

Development of HPV-associated cancers not only depends on efficient negative regulation of cell cycle control that supports the accumulation of genetic damage, but also relies on immune evasion that enable the virus to go undetected for long periods of time. In this way, HPV-related tumors usually p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vici, Patrizia, Mariani, Luciano, Pizzuti, Laura, Sergi, Domenico, Di Lauro, Luigi, Vizza, Enrico, Tomao, Federica, Tomao, Silverio, Cavallotti, Claudia, Paolini, Francesca, Venuti, Aldo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986944/ https://www.ncbi.nlm.nih.gov/pubmed/24667138 http://dx.doi.org/10.1186/1756-9966-33-29

Ejemplares similares

Emerging Biological Treatments for Uterine Cervical Carcinoma
por: Vici, Patrizia, et al.
Publicado: (2014)

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
por: Vici, Patrizia, et al.
Publicado: (2013)

Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?
por: Mazzotta, Marco, et al.
Publicado: (2021)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2021)

Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach
por: Tomao, Federica, et al.
Publicado: (2013)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

Triple-negative breast cancer: new perspectives for targeted therapies
por: Tomao, Federica, et al.
Publicado: (2015)

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
por: Pizzuti, Laura, et al.
Publicado: (2019)

Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies
por: Vici, P, et al.
Publicado: (2016)

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting
por: Di Benedetto, Anna, et al.
Publicado: (2019)

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer
por: Mazzotta, Marco, et al.
Publicado: (2019)

Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2014)

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
por: Papa, Anselmo, et al.
Publicado: (2016)

Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2016)

Albumin-bound formulation of paclitaxel (Abraxane(®) ABI-007) in the treatment of breast cancer
por: Miele, Evelina, et al.
Publicado: (2009)

Current status of bevacizumab in advanced ovarian cancer
por: Tomao, Federica, et al.
Publicado: (2013)

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study
por: Vici, Patrizia, et al.
Publicado: (2011)

Angiogenesis and antiangiogenic agents in cervical cancer
por: Tomao, Federica, et al.
Publicado: (2014)

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
por: Krasniqi, E., et al.
Publicado: (2019)

Fertility drugs, reproductive strategies and ovarian cancer risk
por: Tomao, Federica, et al.
Publicado: (2014)

COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience
por: Barba, Maddalena, et al.
Publicado: (2021)

Plant-Derived Natural Compounds in Genetic Vaccination and Therapy for HPV-Associated Cancers
por: Franconi, Rosella, et al.
Publicado: (2020)

A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer
por: Tomao, Silverio, et al.
Publicado: (2006)

Positron Emission Tomography (PET) radiotracers in oncology – utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC)
por: Miele, Evelina, et al.
Publicado: (2008)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Investigating Molecular Profiles of Ovarian Cancer: An Update on Cancer Stem Cells
por: Tomao, Federica, et al.
Publicado: (2014)

Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting
por: Mandoj, Chiara, et al.
Publicado: (2018)

The synchronous occurrence of squamous cell carcinoma and gastrointestinal stromal tumor (GIST) at esophageal site
por: Spinelli, Gian Paolo, et al.
Publicado: (2008)

Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
por: Rossi, Luigi, et al.
Publicado: (2013)

Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models
por: Venuti, Aldo, et al.
Publicado: (2015)

Bevacizumab in ovarian cancer: A critical review of phase III studies
por: Rossi, Luigi, et al.
Publicado: (2016)

Vitamin D Supplementation and Breast Cancer Prevention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Sperati, Francesca, et al.
Publicado: (2013)

Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial
por: Pizzuti, Laura, et al.
Publicado: (2016)

DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis
por: Vici, Patrizia, et al.
Publicado: (2016)

Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: Description of 2 case reports
por: Gozzi, Elisa, et al.
Publicado: (2020)

Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report
por: Gozzi, Elisa, et al.
Publicado: (2020)

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study
por: Pizzuti, Laura, et al.
Publicado: (2017)

Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases
por: Rossi, Luigi, et al.
Publicado: (2012)

Management of Precancerous Lesions of the Uterine Cervix according to Demographic Data
por: Modinou, Olga, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4jivqtepsanv7jqbqr62ec3q01